Fulcrum Therapeutics, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Fulcrum is a clinical-stage biotechnology company developing small molecules for genetically defined rare diseases. This filing covers the three months ended March 31, 2024; the financial statements are unaudited. Its two clinical-stage candidates are losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD). Fulcrum has not generated product sales.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Collaboration revenue | $0 | $0.3 million |
| Research and development expense | $19.8 million | $16.7 million |
| General and administrative expense | $10.1 million | $11.5 million |
| Total operating expenses | $29.8 million | $28.2 million |
| Other income, net | $3.0 million | $3.2 million |
| Net loss | $26.9 million | $24.8 million |
| Net loss per share, basic and diluted | $0.43 | $0.41 |
| Net cash used in operating activities | $25.3 million | $24.1 million |
At March 31, 2024, cash and cash equivalents were $39.9 million and marketable securities were $173.4 million, totaling $213.3 million; this was down from $236.2 million at December 31, 2023. Current assets were $218.0 million and current liabilities $10.7 million. Total liabilities were $19.0 million, primarily including $10.1 million of operating lease liabilities; the filing reports no credit facility or committed capital source. The company reported an accumulated deficit of $536.5 million. Operating or profit margins are not meaningful given the absence of product sales and ongoing losses.
Cash, cash equivalents and restricted cash increased $14.5 million during the quarter, largely because marketable-security maturities exceeded purchases. This investing cash flow reflects portfolio movements, not operating cash generation. Financing provided $1.7 million, primarily from employee benefit plan stock issuance. The company recorded $0.3 million of unrealized marketable-security losses and no credit-impairment charge.
Material changes and outlook
- R&D expense rose $3.1 million, mainly from higher external development costs as the losmapimod Phase 3 REACH trial advanced, and higher employee compensation. Losmapimod external R&D expense was $8.3 million; pociredir external expense was $2.1 million.
- G&A expense fell $1.5 million, primarily due to lower employee compensation associated with reduced headcount, partly offset by higher professional services costs, including legal expenses. The company reported no collaboration revenue in Q1 2024 because MyoKardia research services ended in Q4 2023.
- REACH enrolled 260 patients and completed enrollment in September 2023. Fulcrum expects topline results in Q4 2024. The Phase 1b pociredir trial resumed after the FDA lifted its clinical hold in August 2023; revised, more restrictive eligibility criteria have made enrollment difficult. The filing also highlights potential hematologic malignancy and other safety concerns.
- After quarter-end, on May 11, 2024, Fulcrum signed a Sanofi agreement granting Sanofi an exclusive license to commercialize losmapimod outside the United States. The agreement provides for an $80 million upfront payment, up to $975 million in regulatory and sales milestones, and tiered royalties; global development costs are to be shared equally. Fulcrum said the upfront payment was expected and that existing quarter-end cash and securities plus that payment were expected to fund operations into 2027. The company was still evaluating the agreement’s accounting treatment. Separately, the financial-statement liquidity note says existing resources are expected to cover at least 12 months from issuance; both runway statements depend on assumptions and are not guaranteed.
- Fulcrum established a $100 million at-the-market equity program in February 2024 and had sold no shares under it by March 31. Further equity financing could dilute shareholders. Management expects operating losses and negative operating cash flows to continue and says expenses are expected to rise with development activity.
Risks, contingencies and unusual items
The principal business risks include clinical-trial failure or delay, pociredir enrollment and safety, regulatory uncertainty, dependence on third-party manufacturers and trial operators, intellectual-property challenges, and the need for additional financing. A securities class action related to the 2023 pociredir clinical hold remains pending; defendants’ motion to dismiss was pending, and Fulcrum said it intends to defend the case. The filing does not provide a clear estimate of potential damages or a recorded loss for the case. Management reported that disclosure controls were effective and that there was no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether REACH topline data is reported in Q4 2024 and what the results show, including the primary endpoint and supporting endpoints.
- Whether pociredir enrollment progresses under the revised criteria and whether any safety findings affect its development.
- Receipt and accounting recognition of the Sanofi $80 million upfront payment, and the agreement’s development-cost sharing, milestone and royalty terms in practice.
- Actual cash burn and runway versus management’s estimate into 2027, including any use of the $100 million ATM program or other financing.
- Developments in the securities class action and any effect on expenses or potential liabilities.